Business · 06/04/2016
FDA Renews Bone, Reproductive and Urologic Drugs Advisory Committee for 2 Years
The FDA has renewed the Bone, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on March 23, 2018.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →